Large gap with delayed quotes
|
Last quote
04/30/2026
-
16:59:50
|
Bid
04/30/2026 -
17:09:59
|
Bid Volume |
Ask
04/30/2026 -
17:09:59
|
Ask Volume |
|---|---|---|---|---|
|
299.40
-1.60
(
-0.53% )
|
300.30
|
50 |
300.70
|
228 |
Analysis date: 28.04.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 24.04.2026.
Interest
Weak
Weak
Two stars since 24.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 17.04.2026 at a price of 329.30.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 21.04.2026.
4wk Rel Perf
1.86%
1.86%
The four-week dividend-adjusted overperformance versus STOXX600 is 1.86%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.71%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.57%.
Mkt Cap in $bn
3.37
3.37
With a market capitalization between $2 & $8bn, ZEALAND PHARMA is considered a mid-cap stock.
G/PE Ratio
-5.31
-5.31
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-6
-6
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-31.85%
-31.85%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
181
181
For 1% of index variation, the stock varies on average by 1.81%.
Correlation
0.37
0.37
Stock movements are strongly independent of index variations.
Value at Risk
167.22
167.22
The value at risk is estimated at DKK 167.22. The risk is therefore 54.12%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
24.02.2017
24.02.2017